Britain and America have signed a key commercial pact that will keep zero duties on UK medicine exports being sold in the US market.
Key Provisions of the Deal
As part of the deal, the UK has pledged to boost funding on medicines through the NHS. This move secures that duties on these vital goods will remain at nothing for a period of 36 months.
This deal comes after recent warnings to hike duties on branded drug imports, with potential rates discussed as high as 100%.
"This deal between the Britain strengthens the worldwide climate for new treatments and establishes long-overdue equity to American-British pharmaceutical trade," a release declared.
Economic Impact
Medicines are one of the Britain's most significant exports to the America, which is by far the primary buyer for large British pharmaceutical firms.
Export figures reveal that in the one-year period leading up to the third quarter, the UK sold medicines totaling billions to the US. This amount made up 17.4% of British export trade in that span.
"This agreement protects work, boosts investment and sets the stage for the UK to emerge as a worldwide center for life sciences," a minister stated.
Detailed UK Commitments
The agreement includes several specific pledges from the UK:
- Price Threshold Increase: The UK will increase the affordability limit at which it considers new treatments to be too expensive by 25%.
- Boosted Medicine Funding: There is a target to raise total NHS spending on drugs from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The amount manufacturers must pay back to the NHS to prevent overspending will be capped at 15%. Previously, repayments topped 20%.
Industry Background
The deal follows a long-running dispute between the drug companies and the British authorities over spending levels and regulatory access.
These tensions were heightened by claims that US patients were paying significantly more for the identical medicines than people in the Britain and the EU.
Recently, several significant drug company projects in the UK have been paused or abandoned, while multi-billion-dollar funding commitments have been pledged toward US facilities.
One official publicly accepted that the NHS had to spend more on medicines, noting that its spending on drugs had declined as a proportion of its resources over the past decade.
